PharmaTher Secured North American 3D Printing Rights
Healthcare operators gain access to new on-demand pharmaceutical printing systems via an exclusive regional distribution deal.
Updated on Oct. 3, 2026 in Healthcare
Live Poll
Do you believe personalized, 3D-printed medicine will improve the quality of your healthcare?
PharmaTher has become the exclusive North American distributor for Craft Health’s 3D printing platform. The agreement provides compounding pharmacies and biotechnology firms with access to integrated printing hardware, software, and consumables.
Why it matters
The deal signals a move toward localized drug manufacturing, allowing specialized facilities to move from centralized inventory to on-site production. Operators in telehealth and hospital settings should monitor this shift as it aims to streamline supply chains through automated, on-demand compounding.
PharmaTher targets over 10,000 potential placement sites for the Craft Health platform across North America. Each installation is expected to generate recurring revenue through the supply of specialized consumables and service agreements.
The players
PharmaTher
A healthcare-focused distributor providing specialized equipment, validation, and technical services to institutional clients.
Craft Health
A Singapore-based developer of pharmaceutical 3D printing technology and integrated software systems.
The details
The platform includes CraftMake hardware, CraftControl software, and proprietary CraftBlends formulations. PharmaTher is responsible for the full operational lifecycle of these units, including installation, technical training, and ongoing system validation for clinical and commercial users. This integrated approach is designed for use by hospitals, CDMOs, and government institutions needing precise, scalable pharmaceutical manufacturing capabilities.
Timeline
Q4 2026: PharmaTher expects to fulfill the initial orders for the printing platform.
Market Landscape
The adoption of pharmaceutical 3D printing platforms represents a transition from traditional batch manufacturing to decentralized, on-demand drug compounding. This deal follows a pattern of increasing investment in modular manufacturing tech designed to integrate directly into hospital and pharmacy workflows.
Operators in the compounding and biotechnology sectors should evaluate if their facility infrastructure can support integrated 3D printing hardware ahead of the Q4 2026 rollout. Assess your current procurement processes for raw material formulations versus the potential for automated, unit-dose manufacturing.
The takeaway
The move suggests a long-term shift toward localized, tech-enabled pharmaceutical manufacturing. Operators should begin monitoring the regulatory requirements and training certifications necessary to integrate advanced printing systems into clinical workflows.
Further reading
For more on industry shifts, visit our Healthcare section.
Live Poll
Do you believe personalized, 3D-printed medicine will improve the quality of your healthcare?
